A global oncology company that is discovering and developing innovative treatments for patients worldwide. Cancer has no borders. Neither do we.
Joined December 2017
- Tweets 1,896
- Following 337
- Followers 5,087
- Likes 507
1,309 Photos and videos
At #EHA2026, we’re sharing new long- term data in patients aged 80 and older – a population often underrepresented in CLL clinical trials despite the disease predominantly affecting older adults.
Hear from Dany Habr, M.D., our Head of Medical Affairs, North America & International Markets, on why these findings matter for clinical practice.
Learn more about BeOne at EHA: beonemedicines.com/stories/e…
#FromFloorToFeed
3
5
202
Jun 12
#News for #Investors and #Media: This weekend at #EHA2026, we’re presenting updated data evaluating our BTK degrader in patients with CLL/SLL.
This data adds to growing research behind next-generation approaches in B- cell malignancies, where resistance and relapse remain ongoing challenges.
Explore the data here: ir.beonemedicines.com/news/b…
#BeOneInnovator
1
1
119
Jun 11
#News for #Investors and #Media:
At #EHA2026, we’re sharing new Phase 3 data in CLL/SLL in patients aged 80 and above to help deepen understanding of a population often underrepresented in clinical research.
Explore the data here: ir.beonemedicines.com/news/b…
#BeOneInnovator
2
2
143
Three days until #EHA2026.
This year, we’re presenting 37 abstracts across hematological cancers, and looking forward to showcasing our findings and shaping where the field goes next. Stay tuned for more.
#TeamBeOne #BeOneAgainstCancer
1
153
CLL treatment has advanced — but patient access hasn’t kept pace.
That’s why we are working with @News_CRA and key partners to release a first-of-its-kind report, 𝙒𝙝𝙚𝙣 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙊𝙪𝙩𝙥𝙖𝙘𝙚𝙨 𝘼𝙘𝙘𝙚𝙨𝙨: 𝘾𝙡𝙤𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙂𝙖𝙥 𝙞𝙣 𝘾𝙇𝙇 𝘾𝙖𝙧𝙚, that explores barriers across the U.S. CLL care journey — from biomarker testing delays to insurance challenges — and the need for more coordinated, patient-centered solutions.
Read more: beonemedicines.com/patients/…
#CLL #BeOneAgainstCancer #ASCO
1
158
At #ASCO26, we're highlighting long-term data in CLL. 78-months of follow-up from a Phase 3 study provides important insight into the importance of durable outcomes. Hear from Amit Agarwal, M.D., Ph.D. on why these data matter just as much as initial response in CLL.
Learn more: beonemedicines.com/stories/a…
#FromFloorToFeed #BeOneAtASCO #TeamBeOne
2
168
#News for #Investors and #Media:
With oral presentations in hepatocellular, gastroesophageal adenocarcinoma and gynecological cancers, our data reflects our focused approach to advancing innovative therapies with speed and purpose, shaping the next generation of options for people living with cancer.
Learn more: ir.beonemedicines.com/news/b…
#BeOneAtASCO #BreastCancer #LiverCancer #ASCO26
3
5
189
May 31
What’s driving momentum behind BeOne’s solid tumor pipeline at #ASCO26? Hear from Dr. Mark Lanasa, Chief Medical Officer, Solid Tumors, as he shares insights on progress across breast, gynecologic, lung, and GI cancers, and what it means for patients.
Learn more: beonemedicines.com/stories/a…
#FromFloorToFeed
1
4
251
May 30
In @USATODAY, we share where the future of CLL is heading and how long-term data is raising the bar. CLL progress has been years in the making, and now shows a meaningful shift from limited options to targeted therapies toward more durable disease control.
Learn more: usatoday.com/story/sponsor-s…
#BeOneInnovator #BeOneAgainstCancer #ASCO26
4
7
240
May 29
#News for #Investors & #Media: Long-term CLL leadership is built on durability, consistency & confidence in first-line treatment decisions. At #ASCO26, we’re unveiling 78-month Phase 3 data for our BTK inhibitor, redefining possibilities for patients.
Learn more: ir.beonemedicines.com/news/b…
#BeOneInnovator
1
3
181
May 28
1 day to go. #ASCO26 kicks off tomorrow, and we’re ready to be immersed in the conversation. With 24 abstracts across hematology and solid tumors, we’ll be sharing new data and connecting with experts to improve patient care. Visit us at Booth 27017 if you’re in Chicago.
Learn more at: beonemedicines.com/stories/a…
#BeOneAtASCO
2
3
161
May 27
#News for #Investors and #Media: Newly published data in The New England Journal of Medicine highlight the results of our Phase 3 clinical trial in the first-line treatment of HER2 gastroesophageal adenocarcinoma. The trial is evaluating a combination regimen that includes our PD-1 inhibitor and a novel HER2-targeted bispecific antibody.
Learn more: ir.beonemedicines.com/news/b…
#ASCO26 #BeOneInnovator
1
5
244
BeOne Medicines retweeted
May 21
Dr. Guillem Lomas talk with soccer goaltender legend @TimHow1x about how cancer touched his life, his partnership with @BeOneMedicines and his #WorldCup experiences and @fifa_world_cup_2026 predictions next on Sports Medicine
2
6
321
May 21
#News for #Investors and #Media:
We’ve got an exciting few weeks ahead. At #ASCO26 and #EHA26, we’re mapping the future of care in B-cell malignancies while showcasing our accelerating solid tumor portfolio. Across both congresses, 60 abstracts highlight the depth of our science and momentum in oncology.
Join us at #ASCO26 and #EHA26 and explore more: ir.beonemedicines.com/news/b…
#BeOneInnovator
3
4
228
May 14
For patients with relapsed or refractory mantle cell lymphoma, options are limited and outcomes can be challenging.
That reality drives our innovation at BeOne.
Our Chief Medical Officer Amit Agarwal, M.D., Ph.D., shares how our BCL2 inhibitor – the first and only in its class FDA-approved in this setting – represents an important step forward for patients who need new options.
Find out more: ir.beonemedicines.com/news/b…
#BeOneInnovator #TeamBeOne
1
5
323
May 13
#News for #Investors and #Media: The U.S. FDA has granted accelerated approval for our foundational BCL2 inhibitor in relapsed/refractory mantle cell lymphoma — the first and only in R/R #MCL.
Full announcement: ir.beonemedicines.com/news/b…
#Oncology #BeOneOnnovator
1
7
14
1,072